Last updated on April 2019

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC


Brief description of study

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Clinical Study Identifier: NCT02273375

Find a site near you

Start Over

Suresnes - Foch

Suresnes, France
2.11miles
  Connect »

Boulogne - Ambroise Pare

Boulogne, France
4.13miles
  Connect »

Versailles - CH Andre Mignot

Le Chesnay, France
4.49miles
  Connect »

Paris - HEGP

Paris, France
5.97miles
  Connect »

HIA Percy

Clamart, France
6.8miles
  Connect »

AP-HP Hopital Tenon

Paris, France
8.17miles
  Connect »

Hopital Bichat

Paris, France
8.17miles
  Connect »

Hopital Saint Louis

Paris, France
8.34miles
  Connect »

Paris - Institut Curie

Paris Cedex 5, France
8.4miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.